MARCKS and breast carcinoma: Using both in vitro and in vivo models of breast cancer, the p-MARCKS was involved in resistance to paclitaxel treatment, with an increased paclitaxel sensitivity after reduction of p-MARCKS by knockdown or by treatment with MANS (p-MARCKS inhibitor peptide targeting the N-terminal myristoylation site) [30].